Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier

被引:45
|
作者
Luker, GD
Rao, VV
Crankshaw, CL
Dahlheimer, J
PiwnicaWorms, D
机构
[1] WASHINGTON UNIV,SCH MED,DEPT RADIOL,LAB MOL RADIOPHARMACOL,ST LOUIS,MO 63110
[2] WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110
关键词
D O I
10.1021/bi971931z
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The multidrug resistance (MDR1) P-glycoprotein functions as a broad specificity efflux transporter of structurally diverse natural product and xenobiotic compounds. P-glycoprotein also is an important component of the functional blood-brain barrier. To enable further studies of function and modulation of MDR1 P-glycoprotein in vitro and in vivo, two novel phosphine technetium(III) complexes were designed and characterized: trans-[2,2'-(1,2-ethanediyldiimino)bis(1,5-methoxy-5-methyl-4-oxohexenyl)]bis[methylbis(3-methoxy-1-propyl)phosphine]Tc(III) (Tc-Q58) and trans-[5,5'-(1,2-ethanediyl diimino)bis(2-ethoxy-2-methyl-3-oxo-4-pentenyl)]bis[dimethyl(3-methoxy-1-propyl)phosphine)]Tc(III) (Tc-Q63). In human drug-sensitive KB 3-1 cells and multidrug-resistant KB 8-5 and 8-5-11 derivative cell lines, expressing nonimmunodetectable, low, and high levels of MDR1 P-glycoprotein, respectively, accumulation of Tc-Q58 and Tc-Q63 was inverse to expression of the transporter. Differences between drug-sensitive and multidrug-resistant cells, while detectable at picomolar concentrations of each radiopharmaceutical, were independent of tracer concentration, Ratios of tracer accumulation in KB 3-1 and 8-5 cells were 62.3 and 48.1 for Tc-Q58 and Tc-Q63, respectively. Cell contents of Tc-Q58 and Tc-Q63 were enhanced up to 60-fold in MDR cells by known modulators of MDR1 P-glycoprotein, while drugs not in the multidrug-resistant phenotype had no effect on their accumulation. In KB 8-5 cells, potency of modulators was GF120918 much greater than cyclosporin A > verapamil. Accumulation of Tc-Q58 and Tc-Q63 in Sf9 insect cells infected with a recombinant baculovirus containing human MDR1 P-glycoprotein was reduced in a GF120918-reversible manner (EC50 less than or equal to 70 nM) compared with cells infected with a wild-type baculovirus. By contrast, cell contents of Tc-Q58 or Tc-Q63 in Sf9 cells expressing the homologous MDR3 P-glycoprotein did not differ from wild-type virus, Demonstrating molecular targeting of these complexes in vivo, distribution and retention of Tc-Q58 in brain tissue of FVB mice treated with a saturating dose of GF120918 and mice deficient in the mdr1a gene [mdr1a (-/-)] were enhanced 180% and 520% over control, respectively. Exploiting the gamma-emission spectrum of Tc-99m, increased uptake of Tc-Q58 in brain tissue of mdr1a (-/-) mice was readily detected noninvasively by scintigraphic imaging. Thus, both Tc-Q58 and Tc-Q63 are demonstrated to be substrates for transport by MDR1 P-glycoprotein, broadening the specificity of this transporter to include phosphine-containing metal complexes. As shown with Tc-Q58, these Q complexes can be used to detect transport activity and modulation of MDR1 P-glycoprotein in vitro and to directly monitor the functional status of P-glycoprotein at the blood-brain barrier in vivo.
引用
收藏
页码:14218 / 14227
页数:10
相关论文
共 50 条
  • [21] P-glycoprotein and multidrug resistance
    Johnston, JMN
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (20): : 1336 - 1336
  • [22] P-GLYCOPROTEIN AND MULTIDRUG RESISTANCE
    SKUBITZ, KM
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1990, 93 (01) : 156 - 157
  • [23] THE MULTIDRUG RESISTANCE P-GLYCOPROTEIN
    HIGGINS, CF
    PEDIATRIC PULMONOLOGY, 1992, : 100 - 100
  • [24] P-GLYCOPROTEIN AND MULTIDRUG RESISTANCE
    LING, V
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1986, : 11 - 11
  • [25] P-glycoprotein and multidrug resistance
    Gottesman, MM
    Pastan, I
    Ambudkar, SV
    CURRENT OPINION IN GENETICS & DEVELOPMENT, 1996, 6 (05) : 610 - 617
  • [26] Antidepressive drugs as substrates of P-glycoprotein at the blood brain barrier
    Uhr, M
    PHARMACOPSYCHIATRY, 2003, 36 (05) : 269 - 269
  • [27] Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein
    Morimoto, Kaori
    Nakakariya, Masanori
    Shirasaka, Yoshiyuki
    Kakinuma, Chihaya
    Fujita, Takuya
    Tamai, Ikumi
    Ogihara, Takuo
    DRUG METABOLISM AND DISPOSITION, 2008, 36 (01) : 6 - 9
  • [28] P-glycoprotein inhibition increases the transport of dauricine across the blood-brain barrier
    Dong, Pei-Liang
    Han, Hua
    Zhang, Tian-Yu
    Yang, Bingyou
    Wang, Qiu-Hong
    Eerdun, Gao-Wa
    MOLECULAR MEDICINE REPORTS, 2014, 9 (03) : 985 - 988
  • [29] Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin
    Zong, J
    Pollack, GM
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 306 (02): : 556 - 562
  • [30] High glucose reduces P-glycoprotein transport activity at the blood-brain barrier
    Chan, Gary N. Y.
    Goldstein, Joyce A.
    Miller, David S.
    DRUG METABOLISM REVIEWS, 2016, 48 : 146 - 146